177-Lu-DOTA-rituximab (University of Basel)

N/A

Report date: 2025/11/24 17:58:31

Base Information

Drug Name177-Lu-DOTA-rituximab (University of Basel)

Drug Alias Name177Lu-DOTA-Rituximab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionCD20-directed cytolytic effectsAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Hospital Basel

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Hospital Basel

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A